The Europe T-Cell therapy Market should witness market growth of 17.2% CAGR during the forecast period (2023-2030).
The expansion of the market is also fueled by increased research studies and clinical trials, as well as private and public investments in advancing cell therapy technology. Additionally, the market is known for its constant evolution and expansion, primarily supported by ongoing research and development initiatives. Scientists and researchers are constantly researching new methods, tools, and therapeutic targets in the growing field of T-cell therapy to boost its efficacy and widen its uses. Additionally, immunotherapy has quickly evolved into what some refer to as the 'fifth pillar'of cancer therapy over the past ten years. That's because immune system-stimulating medications have demonstrated the capacity to reduce and even eliminate tumors in some patients with advanced cancer.
According to the National Cancer Institute, the Food and Drug Administration (FDA) has given approval to six CAR T-cell treatments since 2017. All of them have received approval for treating blood malignancies, such as lymphomas, several varieties of leukemia, and multiple myeloma. The rising prevalence of such malignances has significantly propelled the R&D for developing novel therapies.
According to Myeloma Patients Europe, a pan-European organization, myeloma was identified in around 40,000 people in Europe in the year 2015, and it is anticipated that this number will nearly quadruple to 46,000 by the year 2025. The need for cutting-edge treatments has increased since multiple myeloma prevalence has been increasing in Germany. Due to significant advancements in the development of innovative multiple myeloma treatments, the market is growing. The favorable reimbursement policies offered by the German healthcare system for cancer treatments contribute to the market's rise. Hence, because of all these elements, the region presents lucrative growth prospects for expanding the market throughout the forecast period.
The Germany market dominated the Europe T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $613 million by 2030. The UK market is anticipated to grow at a CAGR of 16.2% during (2023-2030). Additionally, The France market would exhibit a CAGR of 18.1% during (2023-2030).
Based on End-user, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
The expansion of the market is also fueled by increased research studies and clinical trials, as well as private and public investments in advancing cell therapy technology. Additionally, the market is known for its constant evolution and expansion, primarily supported by ongoing research and development initiatives. Scientists and researchers are constantly researching new methods, tools, and therapeutic targets in the growing field of T-cell therapy to boost its efficacy and widen its uses. Additionally, immunotherapy has quickly evolved into what some refer to as the 'fifth pillar'of cancer therapy over the past ten years. That's because immune system-stimulating medications have demonstrated the capacity to reduce and even eliminate tumors in some patients with advanced cancer.
According to the National Cancer Institute, the Food and Drug Administration (FDA) has given approval to six CAR T-cell treatments since 2017. All of them have received approval for treating blood malignancies, such as lymphomas, several varieties of leukemia, and multiple myeloma. The rising prevalence of such malignances has significantly propelled the R&D for developing novel therapies.
According to Myeloma Patients Europe, a pan-European organization, myeloma was identified in around 40,000 people in Europe in the year 2015, and it is anticipated that this number will nearly quadruple to 46,000 by the year 2025. The need for cutting-edge treatments has increased since multiple myeloma prevalence has been increasing in Germany. Due to significant advancements in the development of innovative multiple myeloma treatments, the market is growing. The favorable reimbursement policies offered by the German healthcare system for cancer treatments contribute to the market's rise. Hence, because of all these elements, the region presents lucrative growth prospects for expanding the market throughout the forecast period.
The Germany market dominated the Europe T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $613 million by 2030. The UK market is anticipated to grow at a CAGR of 16.2% during (2023-2030). Additionally, The France market would exhibit a CAGR of 18.1% during (2023-2030).
Based on End-user, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Scope of the Study
By End-user
- Hospitals
- Cancer Treatment Centers
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By Therapy Type
- CAR T-Cell Therapy
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Europe T-Cell therapy Market by End User
Chapter 5. Europe T-Cell therapy Market by Indication
Chapter 6. Europe T-Cell therapy Market by Therapy Type
Chapter 7. Europe T-Cell therapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Methodology
LOADING...
